Loading clinical trials...
Loading clinical trials...
This is a study to characterize the pharmacokinetics as well as safety and tolerability of a single oral dose of EDP-305 in subjects with mild and moderate hepatic impairment compared to matched healt...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Enanta Pharmaceuticals, Inc
NCT06215716 · NASH With Fibrosis, MASH With Fibrosis
NCT06318169 · Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
NCT06843148 · Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Liver Fibrosis/NASH, and more
NCT05842512 · Nonalcoholic Steatohepatitis (NASH)
NCT06661655 · Metabolic Syndrome X, Fatty Liver, and more
American Research Corporation at The Texas Liver Institute
San Antonio, Texas
Pharmaceuticals Research Associates
Prague
Summit SRO
Bratislava
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions